Patents by Inventor Kevin Niswender

Kevin Niswender has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GLP-1R agonists and uses thereof
    Patent number: 11666636
    Abstract: The present disclosure relates to glucagon-like peptide-1 receptor (GLP-1R) agonists and methods of treating or preventing allergic inflammation and/or methods of treating or preventing respiratory syncytial virus (RSV) infection.
    Type: Grant
    Filed: February 14, 2018
    Date of Patent: June 6, 2023
    Assignee: Vanderbilt University
    Inventors: Kevin Niswender, Stokes Peebles
  • GLP-1R AGONISTS AND USES THEREOF
    Publication number: 20190358299
    Abstract: The present disclosure relates to glucagon-like peptide-1 receptor (GLP-1R) agonists and methods of treating or preventing allergic inflammation and/or methods of treating or preventing respiratory syncytial virus (RSV) infection.
    Type: Application
    Filed: February 14, 2018
    Publication date: November 28, 2019
    Inventors: Kevin NISWENDER, Stokes PEEBLES
  • Positive allosteric modulators of the GLP-1 receptor
    Patent number: 10487087
    Abstract: Described are positive allosteric modulators of the GLP-1 receptor, pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for diabetes mellitus type 2, obesity, depression, Alzheimer's disease, Parkinson's disease, Huntington's disease, stroke, cognitive dysfunction, learning disability, and asthma in a subject.
    Type: Grant
    Filed: December 30, 2016
    Date of Patent: November 26, 2019
    Assignee: Vanderbilt University
    Inventors: Craig W. Lindsley, Kevin Niswender
  • POSITIVE ALLOSTERIC MODULATORS OF THE GLP-1 RECEPTOR
    Publication number: 20190010162
    Abstract: Described are positive allosteric modulators of the GLP-1 receptor, pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for diabetes mellitus type 2, obesity, depression, Alzheimer's disease, Parkinson's disease, Huntington's disease, stroke, cognitive dysfunction, learning disability, and asthma in a subject.
    Type: Application
    Filed: December 30, 2016
    Publication date: January 10, 2019
    Inventors: Craig W. Lindsley, Kevin Niswender
  • GLP-1 receptor modulation of addiction, neuropsychiatric disorders and erectile dysfunction
    Publication number: 20120021979
    Abstract: The present invention involves the use of GLP-1 and its analogs or GLP-1 receptor agonists to modulate dopamine transporter signaling. The implications of this ability include the use of MT-1 and its analogs or GLP-1 receptor agonists, such as exendin-4, to blunt behavioral response to addictive drugs, to decrease drug dependence, to prevent drug abuse relapse, and to treat brain disorders such as neuropsychiatric disorders including ADHD. The present invention also involves the use of GLP-1 and its analogs or GLP-1 receptor agonists to activate GLP-1R in penile tissue, such as for the treatment of erectile dysfunction either as a monotherapy or in combinations with other treatments, such as PDE 5 inhibitors.
    Type: Application
    Filed: June 10, 2011
    Publication date: January 26, 2012
    Inventors: Aurelio Galli, Kevin Erreger, Kevin Niswender, Sabrina Robertson, Christine Saunders, Heinrich J.G. Matthies, Adeola Davis